Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia.
Treatment-resistant, chronically hypoxic tumor cells have been assumed to exist in some solid human tumors, limiting their curability. To date, six patients with different types of tumors have been studied using radioactive labelled electron affinic compounds that bind to hypoxic cells. Although the gross clinical appearance of the tumors in all six patients was of a large and fixed mass which might on clinical grounds be expected to contain hypoxic cells, we have observed drug binding to hypoxic regions in only two, a rapidly growing small cell lung cancer (SCLC) and a malignant melanoma. The hypoxic fraction of the malignant melanoma was found to be 6% and the SCLC tumor approximately 10%. We have observed that areas of maximum adduct formation can be found in tumor cells immediately adjacent to blood vessels, suggesting that blood flow over the labelling interval was restricted. These preliminary studies suggest that sensitizer adduct formation in human tumor tissue may be a useful measure of tissue pO2 at the cellular level and that tumor hypoxia might be more related to the rate of tumor growth and histological grading than to tumor size.
D001345:Autoradiography; D018288:Carcinoma, Small Cell / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism; D008545:Melanoma / Q000378:metabolism; D008920:Misonidazole / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism*; D010100:Oxygen / Q000502:physiology*; D014316:Tritium
D014316:Tritium; D008920:Misonidazole; D010100:Oxygen